XTL Biopharmaceuticals Ltd. (XTLB) |
| 1.07 0.387 (56.66%) 01-13 16:00 |
| Open: | 0.867 |
| High: | 1.41 |
| Low: | 0.7501 |
| Volume: | 36,864,032 |
| Market Cap: | 1(M) |
| PE Ratio: | -1.19 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.65 |
| Resistance 1: | 1.41 |
| Pivot price: | 0.72 |
| Support 1: | 0.87 |
| Support 2: | 0.53 |
| 52w High: | 2.57 |
| 52w Low: | 0.53 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Financials
| EPS | -0.900 |
| Book Value | -0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.255 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -853.58 |
| Return on Assets (ttm) | -240.6 |
| Return on Equity (ttm) | -577.1 |
Company news
Tue, 13 Jan 2026
XTL Biopharmaceuticals schedules extraordinary general meeting for February - Investing.com
Tue, 13 Jan 2026
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS - citybiz
Tue, 13 Jan 2026
XTL Biopharmaceuticals Ltd. (XTLB) stock: surged 76% as company enters groundbreaking autism therapeutics market - parameter.io
Tue, 13 Jan 2026
Two Nobel winners back new autism drug push with XTL NeuroNOS deal - Stock Titan
Tue, 13 Jan 2026
Two Nobel laureates back new autism drug effort in XTL’s NeuroNOS deal - Stock Titan
Wed, 31 Dec 2025
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results - The Globe and Mail
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
